Currently out of the existing stock ratings of Mathew Blackman, 39 are a HOLD (41.05%), 56 are a BUY (58.95%).

Mathew Blackman

Work Performance Price Targets & Ratings Chart

Analyst Mathew Blackman works at STIFEL with a stock forecast success ratio of 60.2% fulfilled within 132.56 days on average.

Mathew Blackman’s has documented 186 price targets and ratings displayed on 16 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on GMED, Globus Medical at 08-May-2024.

Wall Street Analyst Mathew Blackman

Analyst best performing recommendations are on ELGX (ENDOLOGIX).
The best stock recommendation documented was for DXCM (DEXCOM) at 4/29/2020. The price target of $96.25 was fulfilled within 8 days with a profit of $9.88 (11.44%) receiving and performance score of 14.3.

Average potential price target upside

AHCO Adapthealth Corp ATEC Alphatec Holdings CERS Cerus DXCM DexCom GMED Globus Medical NUVA NuVasive OFIX Orthofix Medical SENS Senseonics Holdings SPNE SeaSpine Holdings Corp CSII Cardiovascular Systems ELGX Endologix INGN Inogen APEN Apollo Endosurgery PODD Insulet TNDM Tandem Diabetes Care WMGI Wright Medical Group N.V

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

13

$3.02 (30.26%)

13

3 days ago

3/13 (23.08%)

$3.16 (32.11%)

98

Buy

13

$3.02 (30.26%)

13

2 months 14 days ago

0/5 (0%)

$2.48 (23.57%)

Buy

13

$3.02 (30.26%)

9

2 months 20 days ago

2/8 (25%)

$2.73 (26.58%)

91

Hold

8

$-1.98 (-19.84%)

14

6 months 10 days ago

6/13 (46.15%)

$1.5 (23.08%)

50

Buy

14

$4.02 (40.28%)

17

6 months 10 days ago

1/10 (10%)

$7.5 (115.38%)

113

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Mathew Blackman is most bullish on?

Potential upside of $38.75 has been obtained for PODD (INSULET)

Which stock is Mathew Blackman is most reserved on?

Potential downside of $5.6 has been obtained for GMED (GLOBUS MEDICAL)

What Year was the first public recommendation made by Mathew Blackman?

On 2013

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?